Why the study?
The study was conducted to provide an update regarding the safety profile of tinzaparin prescribed as prophylactic or therapeutic regimens for venous thromboembolism in special populations, including cancer and renal impairment.
Does tinzaparin have a safe bleeding and bioaccumulation profile in cancer patients and patients with renal impairment?
Does tinzaparin have a safe bleeding and bioaccumulation profile in cancer patients and patients with renal impairment?
Tinzaparin can be safely used without dose adjustment in patients with severe renal impairment (creatinine clearance > 20 ml/min) and exhibits lower rates of clinically relevant nonmajor bleeding compared to vitamin K antagonists in cancer patients.
Answers are grounded in this paper and cite their sources.
Tinzaparin may be considered in cancer and renal-impaired patients; leaves open need for randomized trials before changing practice.
Low-molecular-weight heparins are approved for primary and secondary venous thromboembolism prevention. Tinzaparin is the low-molecular-weight heparin with the highest average molecular weight. The purpose of this systematic review is to provide an update regarding the safety profile of tinzaparin, prescribed either as a prophylactic or as a therapeutic regimen for venous thromboembolism in special populations, including cancer patients and patients with renal impairment. We identified prospective studies up to August 2020 reporting safety outcomes for cancer patients and patients with renal impairment on tinzaparin regimens. In patients with cancer major bleeding rates fluctuated between 0.8% and 7%. Patients on tinzaparin exhibited significantly lower rates of clinically relevant nonmajor bleeding events in comparison with those on vitamin K antagonists. Bioaccumulation of tinzaparin was not correlated with age, body weight or creatinine clearance. Periodic administration of either prophylactic or therapeutic doses of tinzaparin did not result in bioaccumulation, even in patients with severe renal impairment and creatinine clearance < 20 ml/min. Major bleeding rates for non-cancer patients with renal impairment on prophylactic tinzaparin regimens were 0%. Non-cancer patients with renal impairment on therapeutic tinzaparin regimens exhibited major bleeding in 0 to 3.4% of cases; major bleeding rates were higher for cancer patients with renal impairment on therapeutic tinzaparin regimens (4.3 to 10%). Tinzaparin can be used without dose adjustment in patients with severe renal impairment and creatinine clearance > 20 ml/min. Tinzaparin represents a safe choice for special populations at increased risk for thrombosis and bleeding.
No takes yet. Share an insight, caveat, or question.
Vathiotis et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: